SEC Company Response from Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — Feb 13, 2013
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: Feb. 13, 2013 · CIK: 0001412486 · Accession: 0001521536-13-000128
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-176951
Letter
BioZone Pharmaceuticals, Inc.
550 Sylvan Avenue, Suite 101
Englewood Cliffs, NJ 07632
February 13, 2013
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jennifer Riegel
Jeffery P. Riedler
Re: BioZone Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-176951
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), BioZone Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:30 pm., Washington D.C. time, on February 14, 2013, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
BIOZONE PHARMACEUTICALS, INC.
By: /s/ Elliot Maza
Name: Elliot Maza
Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm BioZone Pharmaceuticals, Inc. 550 Sylvan Avenue, Suite 101 Englewood Cliffs, NJ 07632 February 13, 2013 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jennifer Riegel Jeffery P. Riedler Re: BioZone Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-176951 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), BioZone Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:30 pm., Washington D.C. time, on February 14, 2013, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. BIOZONE PHARMACEUTICALS, INC. By: /s/ Elliot Maza Name: Elliot Maza Title: Chief Executive Officer